Vir Biotechnology Stock News

George Scangos, Vir Biotechnology president & CEO, joins 'Power Lunch' in an interview with CNBC's Meg Tirrell after Vir secured a $1 billion deal with the U.S. government with it's Covid antibody dru

The United States government has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by GlaxoSmithKline plc (NYSE: GSK ) and Vir Biotechnology Inc (NASDAQ: VIR ). GSK said the deal brought the total number of doses secured for the treatment, sotrovimab, to more than 750,000 globally. The U.S. deliveries of sotrovimab are expected by … Full story available on Benzinga.com

Britain's GlaxoSmithKline plc (LON: GSK) announced in a joint statement with the U.S. based Vir Biotechnology Inc (NASDAQ: VIR) on Wednesday that the U.S. government had agreed to buy about $1.0 billi

A COVID-19 BREAKTHROUGH has been made as UK drugmaker GlaxoSmithKline has signed a huge $1billion deal with US-based Vir Biotechnology.

WASHINGTON, Nov 17 The United States has signed contracts worth roughly US$1 billion (RM4.18 billion) to secure the antibody-based Covid-19 treatment sotrovimab from GSK and Vir Biotechnology, the drugmakers said on Wednesday, with supply

Related Stocks: VIR , FORA , SEM , AVIR , GH , MDGL , PTIX , XBIT , XBI , CAPR ,

Related Stocks: ILMN , VIR ,

Related Stocks: PDD , TNYA , SRZN , DNLI , CNST , SNOW , NRIX , BEAM , VIR ,

Credit Suisse AG raised its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 450.2% in the second quarter, Holdings Channel reports. The institutional investor owned 58,173 shares of the companys stock after purchasing an additional 47,600 shares during the period. Credit Suisse AGs holdings in Vir Biotechnology were worth $2,751,000 as of its most recent filing []

Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered via Intramuscular (IM) administrati

Efficacy results for oral antivirals from Pfizer and Merck are weighing heavily on Vir today.

SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter en

SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outco

SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the H. C. Wainwrig